US Patent 8257706 CD30 binding agents and uses thereof
Patent 8257706 was granted and assigned to Seagen on September, 2012 by the United States Patent and Trademark Office.
All edits
Edits on 4 Apr, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 21 Mar, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 29 Nov, 2023
Golden AI
Edits made to:
Article (+167 characters)
Article
Patent abstract
This invention relates to CD30 binding agents and methods of using such binding agents for treating disease characterized by expression of CD30 antigen.
Edits on 21 Sep, 2023
Golden AI
Edits made to:
Infobox (+2 properties)
Infobox
Patent Inventor Names
Charlotte McDonagh0
Paul Carter0
Edits on 25 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 08257706 CD30 binding agents and uses thereof US Patent 8257706 CD30 binding agents and uses thereof
Infobox
Patent Number
082577060
Patent Number
82577060
Edits on 27 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
082577060
Date of Patent
September 4, 2012
0Patent Application Number
124386040
Date Filed
August 24, 2007
0Patent Primary Examiner
Edits on 15 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 08257706 CD30 binding agents and uses thereof
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
08257706
Date of patent
September 4, 2012
Patent application number
12438604
Date Filed
August 24, 2007
Patent primary examiner
Find more entities like US Patent 8257706 CD30 binding agents and uses thereof
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.